Get the latest news, insights, and market updates on PRAX (Praxis Precision Medicines, Inc.). Explore the news page 8 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Praxis Precision Medicines Reports Positive Phase 3 Results for Ulixacaltamide in Essential Tremor
Praxis Precision Medicines Inc. (NASDAQ:PRAX) is one of the Reddit stocks that will go to the moon. On October 16, Praxis Precision Medicines announced positive topline results for its pivotal Phase 3 Essential3 program for ulixacaltamide in essential tremor/ET. Ulixacaltamide is a differentiated, highly selective small molecule inhibitor of T-type calcium channels designed to block […] Oct 22, 2025 - $PRAX
Tesla, Nvidia, Rigetti, Praxis: Trending Stocks
Tesla (TSLA) continued its slide in the pre-market on another bearish analyst report, and mounting questions around Elon Musk company's ability to deliver on robotics and AI promises. Nvidia (NVDA) shares swing down then recover some ground ahead of the open. Meta (META) is close to a $30 billion financing deal for a data center in Louisiana, and shares of its AI glasses partner EssilorLuxottica (EL.PA) hit a new record. Micron (MU) abandons some of its chip supplying activities in China. Other top gainers and losers include Praxis (PRAX) and Rigetti (RGTI). For more live coverage of markets watch the full episode of Market Sunrise and head to Yahoo Finance. Oct 17, 2025 - $PRAX
Praxis Precision (PRAX) Triples on Stellar Drug Trial Results
We recently published Market Downturn? Not for these 10 Stocks; 7 Jump to Record Highs. Praxis Precision Medicines, Inc. (NASDAQ:PRAX) is one of the best performers on Thursday. Praxis Precision soared to a new all-time high on Thursday, more than tripling its share price during the intraday session, as investors celebrated the stellar results of […] Oct 17, 2025 - $PRAX
Praxis Precision Medicines, Inc. Announces Pricing of $525 Million Public Offering
BOSTON, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced the pricing of its underwritten public offering of 3,025,480 shares of its common stock at a public offering price per share of $157.00 and, in lieu of shares of common stock, pre-funde Oct 17, 2025 - $PRAX
Praxis Precision Medicines, Inc. Announces Proposed Public Offering
BOSTON, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced a proposed public offering of its common stock and, in lieu of common stock to certain investors, prefunded warrants to purchase shares of common stock. All securities in the offering w Oct 16, 2025 - $PRAX
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple